Featured Research

from universities, journals, and other organizations

Blacks less likely to know they have heart condition or to use treatment for it, study suggests

Date:
February 26, 2010
Source:
Mayo Clinic
Summary:
A large nationwide study has found that blacks are substantially less likely than whites to know that they have atrial fibrillation or to use warfarin, the most common treatment for the condition. Atrial fibrillation, an abnormal heart rhythm, significantly increases risk of stroke. Warfarin is known to reduce that risk.

A large nationwide study that includes neurologists from Mayo Clinic has found that blacks are substantially less likely than whites to know that they have atrial fibrillation or to use warfarin, the most common treatment for the condition. Atrial fibrillation, an abnormal heart rhythm, significantly increases risk of stroke. Warfarin is known to reduce that risk.

Researchers say the findings could help explain why the black population in the U.S. has a higher incidence of both stroke and death from strokes, compared to the white population. They presented their findings at the American Heart Association's 2010 International Stroke Conference in San Antonio. The study will also be simultaneously published in Stroke: Journal of the American Heart Association.

"The reasons for the racial discrepancy are not known," says James Meschia, M.D., Mayo Clinic neurologist and director of the Comprehensive Stroke Center at Mayo's campus in Florida. "But they are consistent with other studies that show blacks are less likely to receive the care they need to treat stroke risk factors such as diabetes and hypertension."

"These findings should lend urgency to focused efforts to improve patient education and medical treatment across the board," says Dr. Meschia, who who is presenting the findings on behalf of investigators participating in the study, known as REGARDS (The Reasons for Geographic and Racial Differences in Stroke).

From 2003 to 2007, REGARDS enrolled 30,239 men and it deliberately "oversampled" blacks (42 percent) as well as residents of the Southeastern "Stroke Belt." Fifty-six percent were from North Carolina, South Carolina, Georgia, Alabama, Mississippi, Tennessee, Arkansas, and Louisiana, and 44 percent were from other areas of the country. All residents of Stroke Belt states are known to have high stroke death rates, but blacks are at even greater risk, Both blacks and residents of these states are known to have high stroke death rates according to the National Institutes of Health.

For this study, atrial fibrillation was diagnosed using an electrocardiogram (ECG) test given to participants in their homes. Before the visit, participants were asked by telephone if a physician or a health professional had ever told them that they had atrial fibrillation, and they were also asked what medications they were using.

Of those participants whose ECG showed atrial fibrillation, 88 (20 percent) were black, and 344 were white. While 60 percent of the total group (black and white) were aware of their diagnosis, the odds that blacks knew they had the condition were less than one-third of those reported for whites, researchers say.

They further found that the odds of blacks being treated with warfarin, which reduces stroke risk by 60 percent, were one-fourth those of whites.

In other words, blacks in this study with atrial fibrillation were two-thirds less likely to know they had the disorder and three-fourths less likely to be treated with warfarin, the standard of care.

Reasons for the racial disparity are not known from this study, but researchers suggest several explanations. Many study participants might have been undiagnosed because atrial fibrillation is often not symptomatic, Dr. Meschia says. Or, participants may have been diagnosed but did not remember or fully appreciate the significance of the condition, he says. Dr. Meschia says other possible reasons could include utilization or delivery of health care, reluctance by physicians to use warfarin in patients with multiple health conditions, or disinclination by patients to use the drug.

Insurance status was not a factor, the researchers add, because the majority of study participants were over age 65 and were covered by Medicare.

"Whatever the reasons behind these observations, it appears that there is a missed opportunity to prevent stroke and other thromboembolic complications from atrial fibrillation because many individuals may fail to have the condition diagnosed and/or fail to receive treatment with warfarin," Dr. Meschia says. "It would benefit public health if future research could tease out the reasons behind this disparity."

The study was funded by a grant from the National Institute for Neurological Disorders and Stroke, a branch of the National Institutes of Health.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Blacks less likely to know they have heart condition or to use treatment for it, study suggests." ScienceDaily. ScienceDaily, 26 February 2010. <www.sciencedaily.com/releases/2010/02/100226101332.htm>.
Mayo Clinic. (2010, February 26). Blacks less likely to know they have heart condition or to use treatment for it, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/02/100226101332.htm
Mayo Clinic. "Blacks less likely to know they have heart condition or to use treatment for it, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/02/100226101332.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins